A promising strategy involves targeting molecular drivers like the epidermal growth factor receptor (EGFR), a member of the Epidermal growth factor receptor (ErbB) family of receptor tyrosine kinases, which is overexpressed in aggressive breast cancers and associated with poor clinical outcomes (Yarden and Sliwkowski 2001; Masuda et al. 2012). This evidence concerns the gene EGFR and breast carcinoma.